Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q1 EPS of ($0.48), $0.14 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $64.9 million versus the consensus estimate of $71.84 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.